Explore All 3115 Add-on Acquisition Life Science Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | May 1, 2019 |
| Target | Pernix Therapeutics Holdings |
| Sector | Life Science |
| Buyer(s) | Currax Pharmaceuticals |
| Deal Type | Add-on Acquisition |
| Deal Value | 76M USD |
| Advisor(s) | Guggenheim Securities Ernst & Young Capital Advisors (Financial) Davis Polk & Wardwell (Legal) |
FILTER BY
Currax Pharmaceuticals LLC is a specialty pharmaceutical business focused on acquiring and commercializing prescription drugs within the U.S. market. Currax distributes a range of both Branded and generic pharmaceutical products, including Silenor®, Treximet®, Zohydro® ER with BeadTek® and the authorized generic of Treximet®.
| Deal Context for Buyer | # |
|---|---|
| Overall | 1 of 2 |
| Sector: Life Science | 1 of 2 |
| Type: Add-on Acquisition | 1 of 2 |
| State: New Jersey | 1 of 1 |
| Country: United States | 1 of 2 |
| Year: 2019 | 1 of 2 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-09-27 |
Nalpropion Pharmaceuticals
San Diego, California, United States Nalpropion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of weight loss. Nalpropion Pharmaceuticals was formed in 2018 and is based in San Diego, California. |
Buy | - |
